The Hidden Consequences of America’s Weight Loss Drug Boom

Are GLP-1 weight loss drugs changing America—for better or worse? Michael explores the surprising ripple effects of drugs like Ozempic and Wegovy with PwC consumer markets leader Ali Furman. From gyms and grocery stores to travel, fashion, alcohol, gambling, and wellness, this conversation looks beyond weight loss to how these drugs may be reshaping consumer behavior, the economy, and even compulsive habits. Callers weigh in with real-world experiences that challenge assumptions about fitness, motivation, and what a “healthier society” really means. Original air date 15 January 2026.